
Loading, please wait...

Loading, please wait...

Managing patients with atrial fibrillation often requires a dual approach focusing on rhythm control and stroke prevention. Traditionally, catheter ablation for rhythm management and percutaneous left atrial appendage occlusion (LAAO) for stroke risk reduction are performed as separate interventions. However, the strategy of concomitant AF ablation and LAAO in a single clinical session is gaining traction to improve procedural efficiency and reduce the cumulative risks associated with multiple access surgeries.
Recent evidence from a large-scale retrospective cohort study suggests that the combined approach does not compromise patient safety. After matching patients for various comorbidities and baseline characteristics, researchers found that the incidence of adverse events was remarkably similar between those receiving the combined treatment and those undergoing LAAO alone. Specifically, mortality rates remained low and balanced at both 90 days and the one-year follow-up mark.
Beyond early periprocedural safety, the study evaluated long-term outcomes such as stroke, device-related thrombus, and device leak. The data revealed no significant differences in these critical complications over 12 months. These findings support the use of concomitant AF ablation as a viable and safe strategy for appropriately selected patients, potentially streamlining the care pathway for complex cardiac cases.
Performing both procedures at once reduces the need for multiple hospital admissions and lessens the total number of invasive access sessions, which may lower the overall burden on the patient.
Clinical data indicates that the risk of stroke, device-related thrombus, and other complications at one year is comparable to performing LAAO as a standalone procedure.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Sawalha K et al. Safety and Outcomes of Concomitant Left Atrial Appendage Occlusion and Atrial Fibrillation Ablation. JACC Adv. 2026 Jun 11. doi: undefined. PMID: 42275683.
Wazni O et al. Left Atrial Appendage Occlusion vs. Oral Anticoagulation After Catheter Ablation: The OPTION Trial. New England Journal of Medicine. 2024 Nov. doi: 10.1056/NEJMoa2412239.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A large propensity-matched study indicates that performing AF ablation and left atrial appendage occlusion (LAAO) in a single session is as safe as LAAO alone, with similar rates of stroke and mortality at one year.
4 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today